JMP Securities Reiterates Market Outperform on Madrigal Pharmaceuticals, Maintains $383 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $383.
November 14, 2023 | 5:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben reaffirmed a positive 'Market Outperform' rating for Madrigal Pharmaceuticals, with a price target of $383.
The reiteration of a 'Market Outperform' rating by a reputable analyst like Jonathan Wolleben is likely to instill confidence in investors and could positively influence Madrigal Pharmaceuticals' stock price in the short term. The maintained price target of $383 suggests a significant upside potential from the current trading price, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100